Antiphospholipid antibodies and fetal loss

Michael D. Lockshin, Lisa R. Sammaritano, D. Ware Branch, Donald J. Dudley, James R. Scott, Robert M. Silver, Azzudin E. Gharavi, Ronald A. Asherson, E. Nigel Harris, Joseph A. Spinnato, Silvia Pierangeli, m. Birdsall, N. S. Pattison, Claire Infante-Rivard, Michèle David, Robert Gauthier, Georges Etienne Rivard

Research output: Contribution to journalLetterpeer-review

7 Scopus citations


To the Editor: Infante-Rivard and colleagues (Oct. lO issue)1 make an important point that enzyme-linked immunosorbent assays (ELISAs) that can detect low titers of lupus anticoagulant and antiphospholipid antibodies do not distinguish between normal pregnant women and women who have recently had a first miscarriage. However, in stating that “previous investigators have postulated that lupus anticoagulants or anticardiolipin antibodies become risk factors only after a number of fetal losses,” the authors misread earlier data and attempt to answer a question that their study cannot ask. There is consensus that antiphospholipid antibody, used as a marker, is rarely present in normal.

Original languageEnglish (US)
Pages (from-to)951-954
Number of pages4
JournalNew England Journal of Medicine
Issue number14
StatePublished - Apr 2 1992
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Antiphospholipid antibodies and fetal loss'. Together they form a unique fingerprint.

Cite this